Introduction
The familial breast cancer genes BRCA1,2 and TP53 account for less than 10% of all breast cancers (Ford and Easton 1995) . The aetiopathogenesis of nonfamilial breast cancer (490% of cases) is not well understood, but multiple somatic mutations have been described, for instance, the ampli®cation of MYC, ERBB2, and genes at chromosome 11q13; the inactivation of tumour suppressor genes, identi®ed by LOH analysis, described at dierent regions of the genome at frequencies of 20 ± 60% (reviewed in (Bieche and Lidereau 1995) ). We initially identi®ed a locus on chromosome 11q23.3 frequently deleted in breast cancer (Stickland et al., 1992) . Subsequently LOH at 11q22-q23 (20 cM) was con®rmed at a frequency of 30 ± 40% (Carter et al., 1994; Hampton et al., 1994; Koreth et al., 1995a) . The transfer of normal chromosome 11q into the breast cancer cell line MCF-7 suppressed tumorigenicity in vivo, con®rming the existence of a tumour suppressor(s) . Recent reports have suggested two independent deletions on 11q in breast cancer, viz. at 11q22-q23 and 11q23.3 .
LOH at 11q (and particularly 11q22-q23.3) has been reported in a variety of disparate solid tumours including malignant melanoma (Herbst et al., 1995; Tomlinson et al., 1993) , paraganglioma (Devilee et al., 1994) , cervical (Bethwaite et al., 1995; Hampton et al., 1994) , ovarian (Davis et al., 1996; Foulkes et al., 1993; Gabra et al., 1995 Gabra et al., , 1996 , gastric (Baa et al., 1996) , lung , bladder (Shaw and Knowles 1995) and possibly colorectal cancer (Gustafson et al., 1994; Keldysh et al., 1993) . Interestingly, tumour suppression by transfer of chromosome 11 occurs in several tumour cell lines including cervix (Saxon et al., 1986) , lung (Parshad et al., 1992) , melanoma (Coleman et al., 1995) as well as breast cell lines .
The aim here was to delineate the region(s) of 11q involved in sporadic breast and colorectal cancer pathogenesis. Microsatellite mapping analysis of chromosome 11q14-q25 in breast and colorectal cancer de®ne two regions on 11q frequently lost in breast but not in colorectal cancer.
Results

Breast cancer
Archival cases Chromosome 11q allelic data for the 37 matched tumour and constitutional DNA pairs is depicted in Figure 1 . Of these, four (11%) had allelic imbalance (AI) at all loci, suggesting hemichromosome loss (grey bars), 25 (67%) had AI spanning D11S35 and/or D11S897 and 17 (46%) had AI across D11S969 and/or D11S387. Two discrete regions of AI were mapped to 11q22-q23.1 (D11S35-D11S897; *8 Mb) and 11q25 (D11S969-11qterm; *2 Mb). The proximal region of AI was de®ned by cases 22 and 42 mapping AI at D11S35 and cases 9 and 29 showing AI at D11S897. Distally, several cases (e.g. 4, 31, 12, 34) showed telomeric AI at 11q25, with case 4 having AI at D11S387 but not at D11S969, indicating AI distal to D11S969. The presence of markers without AI between the two regions con®rmed the interstitial nature of the mutations (Figures 1 and 3) . Imbalance solely at 11q22-q23.1 occurred in 11 of 37 cases (30%). AI at both 11q22-q23.1 and 11q25 was present in 14 of 37 cases (38%), while AI at 11q25 as the sole event occurred in 3 of 37 cases (8%). The locus D4S127 on chromosome 4p16.3 was assayed as a `background' control in a random subset of 14 cases; AI was detected in 12% (one of eight informative cases).
Fresh cases Fourteen cases were assayed for LOH by microsatellite PCR at ®ve markers spanning 11q22-q25. Deletion mapping produced a similar pattern of allele loss to the archival cases, con®rming two discrete regions of LOH (Figure 2 ). At 11q22-q23.1, six of 12 informative cases (50%) had allele loss, the deleted region being centred around D11S35 in cases 8 and 13. At 11q25, 7 of 14 informative cases (50%) had deletions and cases 11 and 15 had LOH distal to D11S969, a mapping picture identical to the archival series. In case 6, LOH was present at D11S969 but not at the distal D11S387 locus. However, since the deleted region in this case is large (11q14-q25), it overlaps several putative tumour suppressor loci and may not accurately map events at 11q25. Four cases (33%) had allelic deletion in both regions.
Combining the data, from 51 breast cancers analysed, 63% (31 of 49 informative cases) had allele loss at 11q22-q23.1 and 51% (23 of 45 informative cases) at 11q25-qterm. Overall, LOH at 11q occurred in 72% of sporadic breast cancers (37 of 51 cases). There was a signi®cant association between the two deletions occurring together (w c 2 test 4.12; P=0.04).
However, there was no signi®cant association between the deleted regions and the clinical parameters of patient age, tumour size, histopathology and grade and lymph node status.
Colorectal cancer
Thirty primary colorectal cancers collected fresh were assayed by microsatellite PCR at loci on chromosome 11q22, 11q23.3 and 11q25. LOH was detected at 11q22 (D11S35) in 11% (2 of 18 informative cases), at 11q23.3 (D11S29) in 12% (2 of 17 informative cases) and at 11q25 (D11S969) in 15% (three of 20 informative cases). In all, LOH at 11q occurred in ®ve cases (16%). The three markers analysed mapped a region of LOH to 11q23.3-q25. No signi®cant associations with clinicopathological parameters of patients' sex, tumour site and Duke's stage were detected.
Assay validation
In order to de®ne, in statistical terms, the reproducibility of microsatellite PCR set up from mastermixes (except template DNA and Taq polymerase), ®ve replicate reactions of paired tumour and normal tissue were ampli®ed from archival DNA in a case with AI42 ( Figure 4a ). The allelic pattern seen was consistent throughout, with no aberrant alleles or inversion of allele intensity. The allele ratios were calculated for normal and tumour lanes and coecient of variation and standard deviation determined for each data set ( Figure 4b ). The mean allelic imbalance ratio (allele ratio normal/allele ratio tumour) was 2.187 with a coecient of variation of 12.67% and the 95% con®dence intervals at+24.83% from the mean value. Similar results were obtained for PCR ampli®cation of high molecular weight (HMW) genomic DNA from fresh cases and archival DNA, prepared both from mastermixes as well as independently assembled as per protocols (a) and (b), described in the Materials and methods section (CJB, JK, JO'D M; manuscript in preparation).
Discussion
This is our ®rst report using microdissected material from archival tissue for deletion mapping. To address queries regarding the possibility of artefacts during PCR ampli®cation aecting the analysis, a reproducibility assay was performed on HMW genomic DNA from fresh samples and archival microdissected DNA. The analysis showed that mastermix AI assays (the PCR setup method used in this study) from archival microdissected DNA are reproducible and reliable. The allele ratios for normal (N) and tumour (T) lanes could be discriminated with con®dence, with no overlap at+2 standard deviations from each mean (the ranges coincided at+4 standard deviations from each mean).
Hence, with an AI cut-o value of two it is clear that the diering allele intensities re¯ect a change in the sample and are not an artefact of the analytical method used. Further, we had previously demonstrated that AI detected by microsatellite PCR of DNA from archival microdissects correlated with LOH detected by RFLP analysis of HMW genomic DNA prepared from fresh samples of the same tumours (Koreth et al., 1995b) . Finally, ampli®cation of an irrelevant`background' control yielded AI in 12% of cases, a ®gure not signi®cantly dierent from a reported 10%`background' rate of LOH in genomic DNA (Sato et al., 1990 ) from breast tumours (Fisher's exact test; 2 tailed: P=0.5796).
Taken together, data from the archival and fresh breast cancers indicate that allelic deletion occurs distal to chromosome 11q13 in 72% of sporadic breast cancers. We have delineated two putative tumour suppressor loci on chromosome 11q mapping to 11q22-q23.1 (*8 Mb) and 11q25 (*2 Mb), in 63% and 51% of breast cancers respectively. Previous studies identi®ed allele loss at 11q22-q23.3 (20 ± 30 cM) in 42 ± 59% of sporadic breast cancers (Carter et al., 1994; Hampton et al., 1994; Koreth et al., 1995a) and LOH at 11q23 may have prognostic signi®cance, correlating signi®cantly with aggressive post-metastatic disease (Winqvist et al., 1995) . Our interim results from the archival data, published as an abstract (Koreth et al., 1995b) , mapped the least extent of deletion at 11q22-q23 to a single region at 11q22-q23.1. Subsequently, two independent deletions have been reported at 11q22-q23; (a) at 11q22-q23.1 between the markers In the colorectal cases, the ®ve cases with LOH on 11q are displayed and a preliminary deletion map shown. *: heterozygous (informative); no AI: *: heterozygous; AI. nd: not determined. non informative markers are blank D11S2000-D11S897 (510 cM) and (b) at 11q23.3 between the markers D11S528-D11S900 (20 cM) . Region (a) coincides with the 8 Mb region described in this report and previously in abstract form (Koreth et al., 1995b) . Dierences in clinicopathological parameters as well as enrichment for neoplastic cells by microdissection led us to identify LOH in 63% of the cases in our series, a ®gure higher than previously reported. This possibly re¯ects the signi®cant underrepresentation of tumour genetic changes in analysis of macroscopically identi®ed tumour tissue by contaminating DNA from nonneoplastic in®ltrates. In our series, only one case (Figure 2 ; case no. of four) maps to the (b) region of deletion de®ned at 11q23.3 though interstitial deletions overlap this region in several other cases.
LOH at chromosome 11q22-q24 has been described at frequencies ranging from 22 ± 67% in malignant melanoma (Herbst et al., 1995; Tomlinson et al., 1993) , paraganglioma (Devilee et al., 1994) , cervical cancer (Bethwaite et al., 1995; Hampton et al., 1994) , gastric cancer (Baa et al., 1996) , lung adenocarcinoma , and epithelial ovarian cancer (Davis et al., 1996; Foulkes et al., 1993; Gabra et al., 1995 Gabra et al., , 1996 . Mapping studies de®ne a common 11q22-q23 region in all these tumour types, suggesting that a common tumour suppressor gene could be involved. Consistent with our data is the observation that transfer of the normal chromosome 11qcen-q23 region to human breast cancer cell lines suppresses in vivo tumorigenicity in mice. This is functional evidence for a tumour suppressor gene(s) on 11q, probably mapping to 11q13-q23.1 . A similar eect has been demonstrated in cell lines derived from malignant melanoma (Coleman et al., 1995) , cervix (Saxon et al., 1986) and lung adenocarcinoma (Parshad et al., 1992) ; further evidence of a common tumour suppressor gene(s) on 11q in all of these tumour types.
A number of genes have been mapped to the proximal region of deletion at 11q22-q23.1, among them the Ataxia-Telangiectasia (ATM) gene (Savitsky et al., 1995) . Heterozygosity at ATM is known to confer an approximately ®vefold increased risk of breast cancer in aected women, in addition to enhanced susceptibility to a number of other cancers (Swift et al., 1991) . Overlap with the region de®ned here makes ATM a possible candidate for the deleted tumour suppressor. Other candidates, including PGR and ALL-1 do not map to this region (van Heyningen and Little 1995) .
The second region of deletion at chromosome 11q25-qterm, distal to the marker D11S969, occurs in 23/45 (51%) of the cases assayed and has not been identi®ed before. In one study, 43% LOH at the telomeric D11S969 locus has been described (Gud- mundsson et al., 1995), though formal mapping was not undertaken. Interestingly, in our series, in 19 of the 23 cases (82%) with allele loss at 11q25 there is a proximal deletion at 11q22-q23.1, which is not contiguous in 11 cases (58%). The two deletions are signi®cantly associated (w c 2 test 4.12; P=0.04) and may be causally linked. This hypothesis is supported by evidence for a dierence in the degree of the in vivo tumour suppression seen between breast cancer cells transfected with a complete chromosome 11 versus the chromosome 11q arm lacking the qterminal tip, suggesting a possible functional role for gene(s) at 11qterm and an interaction with more proximal gene(s) on 11q . It is likely that loss of the putative tumour suppressor at this site is a speci®c event in breast cancer and not nonspeci®cally associated with the neoplastic state because LOH in this region is not common in colorectal cancer and this dierence is signi®cant (w c 2 test 6.09; P=0.013). This region is distal to the deleted 11q23.3-q24 region described for epithelial ovarian cancer (Davis et al., 1996; Gabra et al., 1995 Gabra et al., , 1996 . We remain unaware of any obvious candidate gene(s) for this novel region. Keldysh et al. (1993) report that LOH at 11q23 occurs in 59% of colorectal cancers, mapping to chromosome 11q22-q23. We ®nd a limited role for gene(s) in the regions 11q22-q25 in this tumour type, with 11 ± 15% of cases showing LOH at three dierent 11q loci. Gustafson et al. (1994) analysing the DRD2 locus (11q23.1), found LOH in 33% of colorectal cancers (23 of 68 cases), in contrast to the ®ndings of Keldysh et al. (1993) . While this manuscript was in preparation another group reported a similar low incidence of 21% LOH at 11q23.1 (DRD2) with LOH rising to 29% at 11q23.3 (D11S29) (Tomlinson and Bodmer, 1996) . Our preliminary mapping of the cases with LOH suggests that in the minority of colorectal cancers with LOH at 11q, the deleted region maps to distal 11q (11q23.3-q25). We do not ®nd evidence that 11q deletions play a signi®cant role in the majority of colorectal cancers.
In conclusion, the expanding list of tumour types with frequent allele loss at 11q23-qterm suggests gene(s) of considerable biological importance in human neoplasia in this region. It is worth noting that after chromosome 17 (the TP53 locus), regions on chromosome 11 (including those mentioned here) are the most frequently lost in human neoplasia (Seizinger et al., 1991) .
Materials and methods
Samples
Archival formalin-®xed, paran embedded constitutional and tumour blocks from 37 nonfamilial breast cancer cases were retrieved from the Departmental archives. Histopathologic 7 m sections were cut and stained with haematoxylin and eosin (H&E). The histopathology was reviewed, tumours typed and graded, and clinicopathological data on patient age, tumour size and lymph node status obtained (Table 1) .
Fresh tumour and adjoining normal tissue was obtained from 14 breast cancer patients undergoing surgery and 30 patients undergoing bowel resection for colorectal cancer.
Tumour and corresponding uninvolved tissue samples were collected, snap frozen and stored in liquid nitrogen. Clinicopathological data for the cases was obtained (Tables  1 and 2 ).
DNA extraction
Microdissection was used to obtain DNA enriched for tumour cells from the 37 archival cases. Brie¯y, selected normal areas and tumour foci with 460% neoplastic cells were microdissected with a single use drawn out glass pipette in a droplet of 20% ethanol. Microdissects from serial sections of each case were pooled and DNA extracted as previously described (Koreth et al., 1995a) .
The fresh breast tumours were cryostat sectioned, histopathology and tumour cell load determined on several sections. The cryosections viewed averaged 440% tumour cells and the intervening 3 ± 5 cryosections were pooled and stored for further analysis. We estimate the total neoplastic cell load varied+5% from the mean. The colorectal tumours were examined grossly and excised. On histopathologic examination all the colorectal cases were adenocarcinomas and the neoplastic cell load was 460%. High molecular weight (HMW) genomic DNA was extracted by standard phenol:chloroform methods and quantitated by spectrophotometry.
Microsatellite PCR
DNA samples were analysed for polymorphic microsatellite repeats at 10 loci on chromosome 11q14-qterm: D11S901 (Litt et al., 1995; van Heyningen and Little, 1995) . A microsatellite on chromosome 4p16.3, D4S127, was selected as a control for background' LOH (Sato et al., 1990) . One of each set of primers was end-labelled with [g-32 P]dATP. Hot-start PCRs were performed in a PerkinElmer 9600 thermal cycler with 10 ml volumes containing 1 mL (microdissects) or 25 ng (genomic) template with 40 ± 100 mM of each dNTP, 3 ± 5 pmole of each primer, 1.5 ± 3.5 mM MgCl 2 and 0.05 units of Taq DNA polymerase. Cycle number, annealing temperatures and extension times were individually optimised for each primer pair (individual parameters available on request). PCR products were resolved on 5% sequencing gels, ®xed, dried and autoradiographed at 7758C using intensifying screens and Kodak X-AR5 ®lm pre-¯ashed to an O.D. of 0.15 (540 nm) for response linearity (Laskey 1990 ). All PCRs were repeated to con®rm results.
AI and LOH analysis
Informative autoradiographs were assessed for AI (archival cases) and LOH (fresh cases) by software densitometric analysis (Quantiscan, Biosoft, UK) using the allelic ratio method, with a cut-o ratio of 2 (archival) and 1.5 (fresh), keeping in mind the dierences in tumour cell load in the specimens (Cawkwell et al., 1993) .
PCR reproducibility assay
Multiple repeat PCRs of HMW genomic and archival DNA were set up (a) from a mastermix of PCR reagents (except template DNA and Taq polymerase, which were aliquoted separately) and (b) independently aliquoting all PCR reagents into separate tubes. Thermal cycling was performed and the products were run out on a sequencing gel, autoradiographed and analysed by software densitometry (Figure 4a) . Area under the peak for upper and lower alleles were determined and allele ratios calculated for each lane. The mean, coecient of variation, standard deviation and 95% con®dence intervals were determined for the data sets.
Results of archival DNA ampli®cation of a case with con®rmed AI42, in 5 replicate pairs prepared from a mastermix (protocol (a)), is shown in Figure 4a and densitometric allele ratios for normal and tumour lanes shown in Figure 4b . Similar results were obtained from both mastermix (a) and independent (b) PCR setups of HMW genomic and archival DNA (CJB, JK, JO'DM; manuscript in preparation).
Statistical analysis
Correlation of clinicopathological parameters and chromosome 11 mutations was assessed by the w 2 test or Fisher's exact test, as appropriate.
